DELPHARM
Supplier & provider
DELPHARM
Description
Delpharm is a worldwide leader in contract manufacturing and development of medicines.
For over 35 years, Delpharm has built up its position by acquiring manufacturing plants over the years, in particular from big pharmaceutical companies. Delpharm’s plants based in Canada, France, Italy, the Netherlands and Poland produce more than a billion boxes of medicines a year.
As multi-specialists, Delpharm is able to supply the majority of pharmaceutical forms available on the market, such as tablets and capsules, bottles and injectable ampoules, prefilled syringes, freeze-drying, suspensions, solutions, ointments and soft gel capsules.
Delpharm also offers full development services for a wide range of pharmaceutical forms, chemical entities and innovative combinations, including the production of phase 1 to 3 clinical batches for solid, semi-solid, liquid and injectable forms.
The company employs more than 6,500 people and has achieved in 2023 a revenue of €1.1 billion.
Committted to optimising and expanding our industrial facilities, Delpharm invests between 80 million euros each year in production facilities.
For over 35 years, Delpharm has built up its position by acquiring manufacturing plants over the years, in particular from big pharmaceutical companies. Delpharm’s plants based in Canada, France, Italy, the Netherlands and Poland produce more than a billion boxes of medicines a year.
As multi-specialists, Delpharm is able to supply the majority of pharmaceutical forms available on the market, such as tablets and capsules, bottles and injectable ampoules, prefilled syringes, freeze-drying, suspensions, solutions, ointments and soft gel capsules.
Delpharm also offers full development services for a wide range of pharmaceutical forms, chemical entities and innovative combinations, including the production of phase 1 to 3 clinical batches for solid, semi-solid, liquid and injectable forms.
The company employs more than 6,500 people and has achieved in 2023 a revenue of €1.1 billion.
Committted to optimising and expanding our industrial facilities, Delpharm invests between 80 million euros each year in production facilities.
Referent Contact
Mathilde Cahu
mathilde.cahu@delpharm.com
DELPHARM
Address
Delpharm DELRIV Port de Boulogne-Billancourt In front of 9 quai du 4 Septembre
92100 Boulogne-Billancourt, Hauts-de-Seine, France
92100 Boulogne-Billancourt, Hauts-de-Seine, France
Contact
biotech-commercial@delpharm.com
Description
Delpharm is a worldwide leader in contract manufacturing and development of medicines.
For over 35 years, Delpharm has built up its position by acquiring manufacturing plants over the years, in particular from big pharmaceutical companies. Delpharm’s plants based in Canada, France, Italy, the Netherlands and Poland produce more than a billion boxes of medicines a year.
As multi-specialists, Delpharm is able to supply the majority of pharmaceutical forms available on the market, such as tablets and capsules, bottles and injectable ampoules, prefilled syringes, freeze-drying, suspensions, solutions, ointments and soft gel capsules.
Delpharm also offers full development services for a wide range of pharmaceutical forms, chemical entities and innovative combinations, including the production of phase 1 to 3 clinical batches for solid, semi-solid, liquid and injectable forms.
The company employs more than 6,500 people and has achieved in 2023 a revenue of €1.1 billion.
Committted to optimising and expanding our industrial facilities, Delpharm invests between 80 million euros each year in production facilities.
For over 35 years, Delpharm has built up its position by acquiring manufacturing plants over the years, in particular from big pharmaceutical companies. Delpharm’s plants based in Canada, France, Italy, the Netherlands and Poland produce more than a billion boxes of medicines a year.
As multi-specialists, Delpharm is able to supply the majority of pharmaceutical forms available on the market, such as tablets and capsules, bottles and injectable ampoules, prefilled syringes, freeze-drying, suspensions, solutions, ointments and soft gel capsules.
Delpharm also offers full development services for a wide range of pharmaceutical forms, chemical entities and innovative combinations, including the production of phase 1 to 3 clinical batches for solid, semi-solid, liquid and injectable forms.
The company employs more than 6,500 people and has achieved in 2023 a revenue of €1.1 billion.
Committted to optimising and expanding our industrial facilities, Delpharm invests between 80 million euros each year in production facilities.
Matchmaking
Connect with DELPHARM
This entity is yours?
Update informationPosition on the value chain
With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.
Bio-resources and biobanking
- Cells, tissues and humanized xeno-organs
- Biosamples
- Viral, phage or bacterial specimen
Identification of biotherapies
- Target identification
- Target validation
- Screening
Drug design
- Drug assessment
- Drug engineering
- In vitro preclinical studies
Clinical validation
- Clinical trials
- In vivo preclinical validation
- Pre-industrial scale production
Production
- Upstream processes
- Downstream processes
- Quality control
Market access
- CE mark / market authorisation
- Payment / Reimbursement
- Care pathways